WO2002036591A3 - Inhalative lösungsformulierung mit einem tiotropiumsalz - Google Patents

Inhalative lösungsformulierung mit einem tiotropiumsalz Download PDF

Info

Publication number
WO2002036591A3
WO2002036591A3 PCT/EP2001/012296 EP0112296W WO0236591A3 WO 2002036591 A3 WO2002036591 A3 WO 2002036591A3 EP 0112296 W EP0112296 W EP 0112296W WO 0236591 A3 WO0236591 A3 WO 0236591A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulation containing
solution formulation
tiotropium salt
inhalative solution
inhalative
Prior art date
Application number
PCT/EP2001/012296
Other languages
English (en)
French (fr)
Other versions
WO2002036591A2 (de
Inventor
Karin Drechsel
Barbara Niklaus-Humke
Christel Schmelzer
Petra Barth
Original Assignee
Boehringer Ingelheim Pharma
Karin Drechsel
Barbara Niklaus-Humke
Christel Schmelzer
Petra Barth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7661727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002036591(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EA200300483A priority Critical patent/EA009068B1/ru
Priority to BR0115016-2A priority patent/BR0115016A/pt
Priority to EEP200300202A priority patent/EE05343B1/xx
Priority to MXPA03003750A priority patent/MXPA03003750A/es
Priority to AU2002221741A priority patent/AU2002221741B2/en
Priority to UA2003054960A priority patent/UA76435C2/uk
Priority to AU2174102A priority patent/AU2174102A/xx
Priority to JP2002539350A priority patent/JP4559703B2/ja
Priority to CA002427583A priority patent/CA2427583C/en
Priority to HU0301377A priority patent/HUP0301377A3/hu
Priority to PL01361001A priority patent/PL361001A1/xx
Application filed by Boehringer Ingelheim Pharma, Karin Drechsel, Barbara Niklaus-Humke, Christel Schmelzer, Petra Barth filed Critical Boehringer Ingelheim Pharma
Priority to KR1020037006001A priority patent/KR100983208B1/ko
Priority to IL15567601A priority patent/IL155676A0/xx
Priority to EP01992710A priority patent/EP1335729A2/de
Priority to NZ526024A priority patent/NZ526024A/en
Priority to SK526-2003A priority patent/SK288031B6/sk
Priority to MEP-2008-407A priority patent/ME00242B/de
Publication of WO2002036591A2 publication Critical patent/WO2002036591A2/de
Publication of WO2002036591A3 publication Critical patent/WO2002036591A3/de
Priority to BG107726A priority patent/BG66425B1/bg
Priority to HR20030337A priority patent/HRP20030337A2/hr
Priority to NO20031914A priority patent/NO332524B1/no
Priority to IL155676A priority patent/IL155676A/en
Priority to HK04103587A priority patent/HK1060569A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft eine treibgasfreie Inhaltionsformulierung von in Wasser oder in einem Gemisch aus Wasser und Ethanol gelöstem Tiotropiumbromid bzw. Tiotropiumbromid-Monohydrat und daraus resultierenden treibgasfreien inhalierbaren Aerosolen.
PCT/EP2001/012296 2000-10-31 2001-10-24 Inhalative lösungsformulierung mit einem tiotropiumsalz WO2002036591A2 (de)

Priority Applications (22)

Application Number Priority Date Filing Date Title
MEP-2008-407A ME00242B (de) 2000-10-31 2001-10-24 Inhalative lösungsformulierung mit einem tiotropiumsalz
IL15567601A IL155676A0 (en) 2000-10-31 2001-10-24 Inhalative solution formulation containing a tiotropium salt
KR1020037006001A KR100983208B1 (ko) 2000-10-31 2001-10-24 티오트로퓸 염을 함유하는 용액의 흡입성 제형
MXPA03003750A MXPA03003750A (es) 2000-10-31 2001-10-24 Formulacion de una solucion de inhalacion con una sal de tiotropio.
BR0115016-2A BR0115016A (pt) 2000-10-31 2001-10-24 Formulação de solução inalativa com um sal de tiotrópio
UA2003054960A UA76435C2 (en) 2000-10-31 2001-10-24 Inhalation formulation of tiotropium salt
AU2174102A AU2174102A (en) 2000-10-31 2001-10-24 Inhalative solution formulation containing a tiotropium salt
EP01992710A EP1335729A2 (de) 2000-10-31 2001-10-24 Inhalative lösungsformulierung mit einem tiotropiumsalz
CA002427583A CA2427583C (en) 2000-10-31 2001-10-24 Inhalable formulation of a solution containing a tiotropium salt
HU0301377A HUP0301377A3 (en) 2000-10-31 2001-10-24 Combination pharmaceutical composition in form of inhalative solution containing a tiotropium salt
PL01361001A PL361001A1 (en) 2000-10-31 2001-10-24 Inhalative solution formulation containing a tiotropium salt
EA200300483A EA009068B1 (ru) 2000-10-31 2001-10-24 Ингаляционная композиция в виде раствора с солью тиотропия
EEP200300202A EE05343B1 (et) 2000-10-31 2001-10-24 Tiotroopiumsoola sisaldav inhaleeritav lahusekompositsioon
AU2002221741A AU2002221741B2 (en) 2000-10-31 2001-10-24 Inhalative solution formulation containing a tiotropium salt
JP2002539350A JP4559703B2 (ja) 2000-10-31 2001-10-24 チオトロピウム塩を含有する溶液の吸入組成物
NZ526024A NZ526024A (en) 2000-10-31 2001-10-24 Inhalative propellant-free solution formulation containing a tiotropium salt
SK526-2003A SK288031B6 (sk) 2000-10-31 2001-10-24 Propellant-free liquid inhalation formulation
BG107726A BG66425B1 (bg) 2000-10-31 2003-04-16 Препарат като инхалационен разтвор, съдържащ тиотропиева сол
HR20030337A HRP20030337A2 (en) 2000-10-31 2003-04-28 Inhalative solution formulation containing a tiotropium salt
NO20031914A NO332524B1 (no) 2000-10-31 2003-04-29 Inhalerbar losningsformulering inneholdende et tiotropiumsalt, slike preparater for anvendelse som medikament samt anvendelse av slike for fremstilling av medikament for behandling av sykdom
IL155676A IL155676A (en) 2000-10-31 2003-04-30 Liquid pharmaceutical composition without propellant containing theotropium salt and other active substance and its use in the preparation of a drug for the treatment of asthma or COPD
HK04103587A HK1060569A1 (en) 2000-10-31 2004-05-20 Inhalative solution formulation containing a tiotropium salt

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10054042 2000-10-31
DE10054042.2 2000-10-31

Publications (2)

Publication Number Publication Date
WO2002036591A2 WO2002036591A2 (de) 2002-05-10
WO2002036591A3 true WO2002036591A3 (de) 2002-07-25

Family

ID=7661727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012296 WO2002036591A2 (de) 2000-10-31 2001-10-24 Inhalative lösungsformulierung mit einem tiotropiumsalz

Country Status (33)

Country Link
EP (1) EP1335729A2 (de)
JP (1) JP4559703B2 (de)
KR (1) KR100983208B1 (de)
CN (1) CN1237970C (de)
AR (1) AR038765A1 (de)
AU (2) AU2002221741B2 (de)
BG (1) BG66425B1 (de)
BR (1) BR0115016A (de)
CA (1) CA2427583C (de)
CZ (1) CZ305033B6 (de)
DE (1) DE10152369A1 (de)
EA (1) EA009068B1 (de)
EC (1) ECSP034570A (de)
EE (1) EE05343B1 (de)
HK (1) HK1060569A1 (de)
HR (1) HRP20030337A2 (de)
HU (1) HUP0301377A3 (de)
IL (2) IL155676A0 (de)
ME (1) ME00242B (de)
MX (1) MXPA03003750A (de)
MY (1) MY132777A (de)
NO (1) NO332524B1 (de)
NZ (1) NZ526024A (de)
PE (1) PE20020518A1 (de)
PL (1) PL361001A1 (de)
SA (1) SA01220503B1 (de)
SK (1) SK288031B6 (de)
TW (1) TWI296934B (de)
UA (1) UA76435C2 (de)
UY (1) UY26991A1 (de)
WO (1) WO2002036591A2 (de)
YU (1) YU33103A (de)
ZA (1) ZA200303045B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070092334A (ko) 2000-04-28 2007-09-12 코산 바이오사이언시즈, 인코포레이티드 폴리케타이드의 제조방법
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
CA2544733A1 (en) * 2003-10-09 2005-04-21 Inverseon, Inc. Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
SI1863476T1 (sl) * 2005-03-16 2016-05-31 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
CA2653744C (en) * 2006-05-26 2018-01-16 Dey, L.P. Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
CN100446770C (zh) * 2007-01-10 2008-12-31 上海现代药物制剂工程研究中心有限公司 丙酸培氯米松水雾剂
TR200907237A2 (tr) * 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropyum kuru toz kombinasyonu
CN116196298A (zh) * 2018-07-26 2023-06-02 四川海思科制药有限公司 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用
CN111936124A (zh) * 2018-07-26 2020-11-13 四川海思科制药有限公司 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504112A2 (de) * 1991-03-14 1992-09-16 Ciba-Geigy Ag Pharmazeutische Aerosolformulierungen
DE4203306A1 (de) * 1992-02-06 1993-08-12 Ig Spruehtechnik Gmbh Asthma oder pulmonal-aerosolzubereitungen mit lecithin
WO1997046243A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
JPH10298107A (ja) * 1997-04-25 1998-11-10 Taisho Pharmaceut Co Ltd 医薬組成物
WO2000007567A1 (de) * 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2183001T3 (es) * 1995-06-27 2003-03-16 Boehringer Ingelheim Pharma Nuevo preparado medicamentoso estable para la produccion de aerosoles exentos de gas propulsor.
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504112A2 (de) * 1991-03-14 1992-09-16 Ciba-Geigy Ag Pharmazeutische Aerosolformulierungen
DE4203306A1 (de) * 1992-02-06 1993-08-12 Ig Spruehtechnik Gmbh Asthma oder pulmonal-aerosolzubereitungen mit lecithin
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
WO1997046243A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
JPH10298107A (ja) * 1997-04-25 1998-11-10 Taisho Pharmaceut Co Ltd 医薬組成物
WO2000007567A1 (de) * 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BALZANO G ET AL: "Effectiveness and acceptability of a domiciliary multidrug inhalation treatment in elderly patients with chronic airflow obstruction: metered dose inhaler versus jet nebulizer.", JOURNAL OF AEROSOL MEDICINE: THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR AEROSOLS IN MEDICINE. UNITED STATES 2000 SPRING, vol. 13, no. 1, April 2000 (2000-04-01), pages 25 - 33, XP001078735, ISSN: 0894-2684 *
MON F ET AL: "AEROSOL THERAPY IN ASTHMA", REVUE DES MALADIES RESPIRATOIRES, vol. 6, no. 3, 1989, pages 189 - 200, XP001078722, ISSN: 0761-8425 *
NACLERIO R M: "Optimizing treatment options.", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 28, no. SUPPL. 6, December 1998 (1998-12-01), pages 54 - 59, XP001078789, ISSN: 0954-7894 *
NISHIMURA KOICHI ET AL: "Additive effect of oxitropium bromide in combination with inhaled corticosteroids in the treatment of elderly patients with chronic asthma.", ALLERGOLOGY INTERNATIONAL, vol. 48, no. 1, March 1999 (1999-03-01), pages 85 - 88, XP001070756, ISSN: 1323-8930 *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 02 26 February 1999 (1999-02-26) *
PAVIA D ET AL: "Preliminary data from phase II studies with Respimat, a propellant-free soft mist inhaler.", JOURNAL OF AEROSOL MEDICINE: THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR AEROSOLS IN MEDICINE. UNITED STATES 1999, vol. 12 Suppl 1, 1999, pages S33 - S39, XP001078739, ISSN: 0894-2684 *
RUTGERS S R ET AL: "Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5'-monophosphate in COPD.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. UNITED STATES MAR 1998, vol. 157, no. 3 Pt 1, March 1998 (1998-03-01), pages 880 - 886, XP001078742, ISSN: 1073-449X *
VAN SCHAYCK C P ET AL: "Periodic treatment regimens with inhaled steroids in asthma or chronic obstructive pulmonary disease. Is it possible?", JAMA: THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. UNITED STATES 12 JUL 1995, vol. 274, no. 2, 12 July 1995 (1995-07-12), pages 161 - 164, XP001078744, ISSN: 0098-7484 *

Also Published As

Publication number Publication date
AR038765A1 (es) 2005-01-26
CZ20031487A3 (cs) 2003-09-17
EA200300483A1 (ru) 2003-12-25
SK288031B6 (sk) 2012-12-03
KR20040010552A (ko) 2004-01-31
PE20020518A1 (es) 2002-07-12
WO2002036591A2 (de) 2002-05-10
EA009068B1 (ru) 2007-10-26
KR100983208B1 (ko) 2010-09-20
NO332524B1 (no) 2012-10-08
HUP0301377A3 (en) 2005-12-28
EE200300202A (et) 2003-10-15
CA2427583A1 (en) 2002-05-10
SK5262003A3 (en) 2003-10-07
AU2002221741B2 (en) 2007-04-05
CZ305033B6 (cs) 2015-04-08
ME00242B (de) 2011-05-10
EP1335729A2 (de) 2003-08-20
NO20031914D0 (no) 2003-04-29
AU2174102A (en) 2002-05-15
YU33103A (sh) 2006-05-25
DE10152369A1 (de) 2002-05-08
CA2427583C (en) 2008-02-12
TWI296934B (en) 2008-05-21
CN1237970C (zh) 2006-01-25
JP4559703B2 (ja) 2010-10-13
JP2004523482A (ja) 2004-08-05
ZA200303045B (en) 2004-04-22
HUP0301377A2 (hu) 2003-10-28
EE05343B1 (et) 2010-10-15
IL155676A (en) 2012-05-31
SA01220503B1 (ar) 2007-03-10
BR0115016A (pt) 2005-05-03
PL361001A1 (en) 2004-09-20
BG66425B1 (bg) 2014-04-30
UA76435C2 (en) 2006-08-15
HK1060569A1 (en) 2004-08-13
BG107726A (bg) 2004-11-30
IL155676A0 (en) 2003-11-23
NZ526024A (en) 2005-10-28
CN1473044A (zh) 2004-02-04
HRP20030337A2 (en) 2005-04-30
MXPA03003750A (es) 2004-10-15
MY132777A (en) 2007-10-31
ECSP034570A (es) 2003-06-25
UY26991A1 (es) 2002-06-20
MEP40708A (en) 2011-02-10
NO20031914L (no) 2003-06-23

Similar Documents

Publication Publication Date Title
WO2002036591A3 (de) Inhalative lösungsformulierung mit einem tiotropiumsalz
AP1572A (en) Crystalline monohydrate, method for producing the same and use thereof in the production of a medicament.
RS76604A (en) Pressuriesed metered dose inhalers containing solutions of beta-2 agonists
CA2359813A1 (en) Nicotine mucosal spray
WO2007064658A3 (en) Safe and effective methods of administering therapeutic agents
WO2007060104A3 (de) Aerosolformulierung für die inhalation enthaltend ein anticholinergikum
AP2003002909A0 (en) A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases.
WO2007060108A3 (de) Aerosolformulierung für die inhalation enthaltend ein anticholinergikum
WO2005030211A8 (de) Aerosolformulierung für die inhalation enthaltend ein anticholinergikum
WO2007137206A3 (en) Unit dose formulations comprising an inhalable solution of albuterol
WO2002036104A3 (de) Inhalative lösungsformulierung mit einem tiotropiumsalz
WO2000066107A3 (en) Antimalarian agents for the treatment of asthma
IL195818A0 (en) Derivatives of 2-benzoyl-imidazopyridines, preparation ,method thereof and use of same in therapeutics
MY137249A (en) Aerosol formulation for inhalation containing a tiotropium salt
JP2003502361A5 (de)
WO2005055717A3 (en) Agrochemical compositions
WO2011077169A3 (en) Pharmaceutical preparation comprising sufentanil
AU2003288107A1 (en) Tiotropium-containing medicament combinations used for inhaling

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200300391

Country of ref document: VN

Ref document number: P-331/03

Country of ref document: YU

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 10772601

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2003/03045

Country of ref document: ZA

Ref document number: 200303045

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: P20030337A

Country of ref document: HR

Ref document number: PA/a/2003/003750

Country of ref document: MX

Ref document number: 03035210

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500304

Country of ref document: PH

Ref document number: 018183271

Country of ref document: CN

Ref document number: 2427583

Country of ref document: CA

Ref document number: 5262003

Country of ref document: SK

Ref document number: 2001992710

Country of ref document: EP

Ref document number: 00649/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020037006001

Country of ref document: KR

Ref document number: 2002539350

Country of ref document: JP

Ref document number: 155676

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002221741

Country of ref document: AU

Ref document number: 200300483

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 526024

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV2003-1487

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 20030802

Country of ref document: UZ

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001992710

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-1487

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020037006001

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 526024

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526024

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002221741

Country of ref document: AU